JP7299209B2 - 癌治療において壊死を標的とするヒト化抗核抗体 - Google Patents

癌治療において壊死を標的とするヒト化抗核抗体 Download PDF

Info

Publication number
JP7299209B2
JP7299209B2 JP2020500785A JP2020500785A JP7299209B2 JP 7299209 B2 JP7299209 B2 JP 7299209B2 JP 2020500785 A JP2020500785 A JP 2020500785A JP 2020500785 A JP2020500785 A JP 2020500785A JP 7299209 B2 JP7299209 B2 JP 7299209B2
Authority
JP
Japan
Prior art keywords
humanized antibody
antibody
seq
humanized
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020500785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511541A (ja
JP2020511541A5 (cg-RX-API-DMAC10.html
Inventor
アラン、エプスタイン
ペイシェン、フー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theraccines Ltd
Original Assignee
Cancer Therapeutics Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Therapeutics Laboratories Inc filed Critical Cancer Therapeutics Laboratories Inc
Publication of JP2020511541A publication Critical patent/JP2020511541A/ja
Publication of JP2020511541A5 publication Critical patent/JP2020511541A5/ja
Priority to JP2023098123A priority Critical patent/JP7624478B2/ja
Application granted granted Critical
Publication of JP7299209B2 publication Critical patent/JP7299209B2/ja
Priority to JP2025008079A priority patent/JP2025066768A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020500785A 2017-03-20 2018-03-19 癌治療において壊死を標的とするヒト化抗核抗体 Active JP7299209B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023098123A JP7624478B2 (ja) 2017-03-20 2023-06-14 癌治療において壊死を標的とするヒト化抗核抗体
JP2025008079A JP2025066768A (ja) 2017-03-20 2025-01-20 癌治療において壊死を標的とするヒト化抗核抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762473554P 2017-03-20 2017-03-20
US62/473,554 2017-03-20
PCT/US2018/023123 WO2018175310A1 (en) 2017-03-20 2018-03-19 Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023098123A Division JP7624478B2 (ja) 2017-03-20 2023-06-14 癌治療において壊死を標的とするヒト化抗核抗体

Publications (3)

Publication Number Publication Date
JP2020511541A JP2020511541A (ja) 2020-04-16
JP2020511541A5 JP2020511541A5 (cg-RX-API-DMAC10.html) 2021-04-30
JP7299209B2 true JP7299209B2 (ja) 2023-06-27

Family

ID=63584724

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020500785A Active JP7299209B2 (ja) 2017-03-20 2018-03-19 癌治療において壊死を標的とするヒト化抗核抗体
JP2023098123A Active JP7624478B2 (ja) 2017-03-20 2023-06-14 癌治療において壊死を標的とするヒト化抗核抗体
JP2025008079A Pending JP2025066768A (ja) 2017-03-20 2025-01-20 癌治療において壊死を標的とするヒト化抗核抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023098123A Active JP7624478B2 (ja) 2017-03-20 2023-06-14 癌治療において壊死を標的とするヒト化抗核抗体
JP2025008079A Pending JP2025066768A (ja) 2017-03-20 2025-01-20 癌治療において壊死を標的とするヒト化抗核抗体

Country Status (8)

Country Link
US (3) US11384157B2 (cg-RX-API-DMAC10.html)
EP (1) EP3601364A4 (cg-RX-API-DMAC10.html)
JP (3) JP7299209B2 (cg-RX-API-DMAC10.html)
KR (2) KR20240148849A (cg-RX-API-DMAC10.html)
CN (2) CN110461878B (cg-RX-API-DMAC10.html)
AU (2) AU2018237046B2 (cg-RX-API-DMAC10.html)
CA (1) CA3056703A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018175310A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023126794A (ja) * 2017-03-20 2023-09-12 キャンサー、セラピューティックス、ラボラトリーズ、インコーポレイテッド 癌治療において壊死を標的とするヒト化抗核抗体

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
LU103248B1 (en) 2024-02-19 2025-08-19 Stratec Se Container handling device
WO2025194038A1 (en) * 2024-03-15 2025-09-18 Caris Science, Inc. Antibody compositions and methods for targeting extracellular nucleosome proteins
US20260027155A1 (en) 2024-07-23 2026-01-29 Immunitybio, Inc. Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517970A (ja) 2003-02-14 2006-08-03 ユニバーシティ オブ サザン カリフォルニア 癌免疫療法のための組成物及び方法
US20160235859A1 (en) 2015-02-18 2016-08-18 The United States Of America As Represented By The Department Of Veterans Affairs Methods for dna-dependent targeting of a cell permeant antibody
JP2017503511A (ja) 2014-01-13 2017-02-02 バレリオン セラピューティクス， エルエルシー 内在化部分

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ581468A (en) * 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
US9260517B2 (en) * 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
GB201220242D0 (en) * 2012-11-09 2012-12-26 Fusion Antibodies Ltd Antibody
US20180194831A1 (en) * 2015-07-10 2018-07-12 Ohio State Innovation Foundation Methods and compositions relating to anti-nucleolin recombinant immunoagents
MX2019004681A (es) * 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
KR20240148849A (ko) 2017-03-20 2024-10-11 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517970A (ja) 2003-02-14 2006-08-03 ユニバーシティ オブ サザン カリフォルニア 癌免疫療法のための組成物及び方法
JP2017503511A (ja) 2014-01-13 2017-02-02 バレリオン セラピューティクス， エルエルシー 内在化部分
US20160235859A1 (en) 2015-02-18 2016-08-18 The United States Of America As Represented By The Department Of Veterans Affairs Methods for dna-dependent targeting of a cell permeant antibody

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS，1998年，Vol.13, No.4，p.255-268
Proceedings of the American Association for Cancer Research.，2002年，Vol.43，p.910,#4512
UPDATE ON CANCER THERAPEUTICS，2006年，Vol.1, No.1，p.33-47

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023126794A (ja) * 2017-03-20 2023-09-12 キャンサー、セラピューティックス、ラボラトリーズ、インコーポレイテッド 癌治療において壊死を標的とするヒト化抗核抗体
JP7624478B2 (ja) 2017-03-20 2025-01-30 キャンサー、セラピューティックス、ラボラトリーズ、インコーポレイテッド 癌治療において壊死を標的とするヒト化抗核抗体

Also Published As

Publication number Publication date
JP2025066768A (ja) 2025-04-23
JP2020511541A (ja) 2020-04-16
AU2018237046A1 (en) 2019-09-26
US20250215114A1 (en) 2025-07-03
CN110461878A (zh) 2019-11-15
KR20240148849A (ko) 2024-10-11
KR20190130604A (ko) 2019-11-22
US12258421B2 (en) 2025-03-25
CN110461878B (zh) 2022-12-09
CA3056703A1 (en) 2018-09-27
US20200157246A1 (en) 2020-05-21
US11384157B2 (en) 2022-07-12
AU2024259793A1 (en) 2025-01-02
KR102698752B1 (ko) 2024-08-26
JP7624478B2 (ja) 2025-01-30
WO2018175310A4 (en) 2018-11-22
JP2023126794A (ja) 2023-09-12
CN115947859A (zh) 2023-04-11
EP3601364A4 (en) 2021-01-06
WO2018175310A1 (en) 2018-09-27
AU2018237046B2 (en) 2024-11-14
EP3601364A1 (en) 2020-02-05
US20230027730A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP7624478B2 (ja) 癌治療において壊死を標的とするヒト化抗核抗体
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
AU2019304174B2 (en) Antibodies specific to folate receptor alpha
JP7805287B2 (ja) 抗ｓｔｅａｐ１抗体およびその使用
JP2020515251A (ja) Ｂ７−ｈ３抗体、その抗原結合フラグメント、及びそれらの医学的使用
AU2022434181B2 (en) Anti-TSLP nanobodies and their applications
CN114341176A (zh) Cd19抗体及其使用方法
JP2024514855A (ja) Ｄｌｌ３に対する結合分子及びその使用
CN114401744A (zh) 用于治疗癌症的抗cd33抗体
JP2024530166A (ja) Ｃｄ３標的化抗体及びそれらの使用
CN118388652B (zh) 抗成纤维细胞活化蛋白的单克隆抗体及其应用
US20170362314A1 (en) Anti-CXCL12 Antibody Molecules and Their Uses
WO2025045032A1 (zh) 一种靶向cd105的抗体或其抗原结合片段及其应用
AU2023274919A1 (en) Anti-cd44v6 antibodies and their use to treat cd44v6 overexpressing cancers
WO2016122250A1 (ko) 항 eprs 모노클로날 항체 및 이의 용도
CN120813379A (zh) 靶向l1cam的抗体及其用途
CN120322460A (zh) 单价cd47结合蛋白
HK40031847B (en) A bcma binding protein and method for preparation and application thereof
HK40031847A (en) A bcma binding protein and method for preparation and application thereof
Putelli Human antibody phage technology-isolation and characterization of monoclonal antibodies for the targeting of cancer and rheumatoid arthritis
Pfaffen Human monoclonal antibodies for the targeting of matrix metalloproteinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230615

R150 Certificate of patent or registration of utility model

Ref document number: 7299209

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250